These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36541031)

  • 21. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
    Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
    JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study.
    Tomowiak C; Leblond V; Laribi K; Baron M; Puppinck C; Gérard P; Courret E; Gorochov G; Sterlin D; Tournilhac O; Morel P; Cymbalista F; Roos-Weil D;
    Br J Haematol; 2022 May; 197(4):424-427. PubMed ID: 35029297
    [No Abstract]   [Full Text] [Related]  

  • 23. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
    Torres I; Bellido-Blasco JB; Gimeno C; Burgos JS; Albert E; Moya-Malo R; Gascó-Laborda JC; Tornero A; Soriano J; Meseguer-Ferrer N; Martínez-Serrano M; Ortíz-Rambla J; Buj H; Hernández N; Peiró S; Salas D; Limón R; Vanaclocha H; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Navarro D;
    J Med Virol; 2022 Aug; 94(8):3776-3782. PubMed ID: 35445415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.
    Doucette EJ; Gray J; Fonseca K; Charlton C; Kanji JN; Tipples G; Kuhn S; Dunn J; Sayers P; Symonds N; Wu G; Freedman SB; Kellner JD
    PLoS One; 2023; 18(4):e0284046. PubMed ID: 37023007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination.
    Butt AA; Nafady-Hego H; Chemaitelly H; Abou-Samra AB; Khal AA; Coyle PV; Kanaani ZA; Kaleeckal AH; Latif AN; Masalmani YA; Bertollini R; Raddad LJA
    Int J Infect Dis; 2021 Sep; 110():353-358. PubMed ID: 34375762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
    Peghin M; De Martino M; Palese A; Gerussi V; Bontempo G; Graziano E; Visintini E; D'Elia D; Dellai F; Marrella F; Fabris M; Curcio F; Sartor A; Isola M; Tascini C
    Clin Microbiol Infect; 2022 Aug; 28(8):1140-1148. PubMed ID: 35339673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of seroconversion after coronavirus disease 2019 vaccination.
    Chiarella SE; Jenkins SM; Smith CY; Prasad V; Shakuntulla F; Ahluwalia V; Iyer VN; Theel ES; Joshi AY
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):189-193. PubMed ID: 35640775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.
    Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM
    Front Immunol; 2021; 12():742914. PubMed ID: 34659237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
    Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
    Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19).
    Lee J; Lee DG; Jung J; Ryu JH; Shin S; Cho SY; Lee R; Oh EJ
    Front Immunol; 2022; 13():1038712. PubMed ID: 36578491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.
    Lee LYW; Tilby M; Starkey T; Ionescu MC; Burnett A; Hattersley R; Khan S; Little M; Liu JKH; Platt JR; Tripathy A; Watts I; Williams ST; Appanna N; Al-Hajji Y; Barnard M; Benny L; Buckley A; Cattell E; Cheng V; Clark J; Eastlake L; Gerrand K; Ghafoor Q; Grumett S; Harper-Wynne C; Kahn R; Lee AJX; Lydon A; McKenzie H; Panneerselvam H; Pascoe J; Patel G; Patel V; Potter V; Randle A; Rigg AS; Robinson T; Roylance R; Roques T; Rozmanowski S; Roux RL; Shah K; Sintler M; Taylor H; Tillett T; Tuthill M; Williams S; Beggs A; Iveson T; Lee SM; Middleton G; Middleton M; Protheroe AS; Fittall MW; Fowler T; Johnson P;
    JAMA Oncol; 2023 Feb; 9(2):188-196. PubMed ID: 36547970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
    Madelon N; Lauper K; Breville G; Sabater Royo I; Goldstein R; Andrey DO; Grifoni A; Sette A; Kaiser L; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
    Clin Infect Dis; 2022 Aug; 75(1):e1037-e1045. PubMed ID: 34791081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
    Moriyama Y; Ishikane M; Ueno M; Matsunaga A; Ishizaka Y; Arashiro T; Kanno T; Suzuki T; Kimura K
    J Infect Chemother; 2022 Jul; 28(7):962-964. PubMed ID: 35461768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.